Fitt Insider Hims & Novo Nordisk Partner, WHOOP Adds Women's Labs, Fitt Insider's Scouting Report Drops
Mar 10, 2026
Breakdown of a pharma settlement letting a telehealth brand offer FDA-approved weight-loss drugs at standard pricing. Coverage of a wearable maker adding an 11‑marker hormone blood test tied to AI and biometric data for women. Preview of a scouting report that spotlights 50 early-stage startups shaping mental, physical, social, environmental, and existential health.
AI Snips
Chapters
Transcript
Episode notes
Hims Drops Copycat GLP-1 Plan
- Novo Nordisk and Hims & Hers agreed to have Hims offer FDA-approved semaglutide drugs at standard telehealth prices and stop advertising compounded GLP-1s.
- The truce follows regulatory pushback over Hims's plan to sell a low-cost copycat GLP-1 pill and narrows compounded use to medically necessary cases.
Whoop Adds Women's Hormone Labs
- WHOOP launched female-focused hormone biomarker testing combining blood tests for 11 markers with wearable data and AI-driven insights across life stages.
- The feature complements Whoop's labs, biological age estimates, and AI coaching as women become the fastest-growing segment (up 150% YoY).
Fitt Insider Scouting Report Maps Wellness Startups
- Fitt Insider released a Scouting Report profiling 50 early-stage startups across mental, physical, social, environmental, and existential health.
- The report maps signals and subcultures in a wellness economy now over $7 trillion to spotlight where innovation is emerging first.